Plasma N -Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.

Objective: Plasma protein N -glycan profiling integrates information on enzymatic protein glycosylation, which is a highly controlled ubiquitous posttranslational modification. Here we investigate the ability of the plasma N -glycome to predict incidence of type 2 diabetes and cardiovascular diseases (CVDs; i.e., myocardial infarction and stroke).
Research Design and Methods: Based on the prospective European Prospective Investigation of Cancer (EPIC)-Potsdam cohort ( n = 27,548), we constructed case-cohorts including a random subsample of 2,500 participants and all physician-verified incident cases of type 2 diabetes ( n = 820; median follow-up time 6.5 years) and CVD ( n = 508; median follow-up time 8.2 years). Information on the relative abundance of 39 N -glycan groups in baseline plasma samples was generated by chromatographic profiling. We selected predictive N -glycans for type 2 diabetes and CVD separately, based on cross-validated machine learning, nonlinear model building, and construction of weighted prediction scores. This workflow for CVD was applied separately in men and women.
Results: The N -glycan-based type 2 diabetes score was strongly predictive for diabetes risk in an internal validation cohort (weighted C-index 0.83, 95% CI 0.78-0.88), and this finding was externally validated in the Finland Cardiovascular Risk Study (FINRISK) cohort. N -glycans were moderately predictive for CVD incidence (weighted C-indices 0.66, 95% CI 0.60-0.72, for men; 0.64, 95% CI 0.55-0.73, for women). Information on the selected N -glycans improved the accuracy of established and clinically applied risk prediction scores for type 2 diabetes and CVD.
Conclusions: Selected N -glycans improve type 2 diabetes and CVD prediction beyond established risk markers. Plasma protein N -glycan profiling may thus be useful for risk stratification in the context of precisely targeted primary prevention of cardiometabolic diseases.
(© 2020 by the American Diabetes Association.)